WMJ-J-09

WMJ-J-09 is an HDAC inhibitor with IC50 values of 7.5 nM (HDAC1), 21.3 nM (HDAC2), 18.4 nM (HDAC3), 90.9 nM (HDAC8), 3.9 nM (HDAC6) and 8715.7 nM (HDAC4) . WMJ-J-09 blocks the cell cycle and induces apoptosis in cancer cells. WMJ-J-09 induces cancer cell death through the LKB1-AMPK-p38MAPK-p63-survivin signaling cascade.WMJ-J-09 inhibits HDAC enzyme activity, leading to acetylation of key proteins and thereby regulating cancer cell death. WMJ-J-09 can be used in HCT116 cells and FaDu cells research[1][2].

Product Specifications

CAS Number

[2416914-29-7]

UNSPSC

12352100

Target

AMPK; Apoptosis; HDAC; MDM-2/p53; Microtubule/Tubulin; p38 MAPK; Pim; Survivin

Related Pathways

Apoptosis; Cell Cycle/DNA Damage; Cytoskeleton; Epigenetics; JAK/STAT Signaling; MAPK/ERK Pathway; PI3K/Akt/mTOR

Field of Research

Cancer

Purity

98.44

Solubility

DMSO : 250 mg/mL (ultrasonic)

Smiles

O=C(NO)CCCCCCC(NC1=CC(N(S(C2=CC=CC=C2)(=O)=O)CC3)=C3C=C1)=O

Molecular Formula

C22H27N3O5S

Molecular Weight

445.53

References & Citations

[1]Hanhuang Yu, et al. The hydroxamate based HDAC inhibitor WMJ-J-09 induces |[2]Chia-Sheng Yen, et al. A Novel Hydroxamate-Based Compound WMJ-J-09 Causes Head and Neck Squamous Cell Carcinoma Cell Death via LKB1-AMPK-p38MAPK-p63-Survivin Cascade. Front Pharmacol. 2018 Mar 1. 9:167.